Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 5
2008 7
2009 7
2010 14
2011 15
2012 15
2013 14
2014 12
2015 6
2016 5
2017 6
2018 2
2019 6
2020 3
2021 3
2022 10
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 21041183

118 results

Results by year

Filters applied: . Clear all
Page 1
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Chambers SK, et al. Clin Cancer Res. 2010 Nov 1;16(21):5320-8. doi: 10.1158/1078-0432.CCR-10-0974. Clin Cancer Res. 2010. PMID: 21041183 Free PMC article. Clinical Trial.
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Cohen EE, et al. Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7. Lancet Oncol. 2009. PMID: 19201650 Free PMC article. Clinical Trial.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. Dickler MN, et al. Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141. Clin Cancer Res. 2008. PMID: 19047117 Free PMC article. Clinical Trial.
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF; Chicago Phase II Consortium; PMH Phase II Consortium; California Phase II Consortium. Nimeiri HS, et al. Gynecol Oncol. 2008 Jul;110(1):49-55. doi: 10.1016/j.ygyno.2008.02.009. Epub 2008 Apr 18. Gynecol Oncol. 2008. PMID: 18423560 Free PMC article. Clinical Trial.
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Sathornsumetee S, et al. Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17. Neuro Oncol. 2010. PMID: 20716591 Free PMC article. Clinical Trial.
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD. Lubner SJ, et al. J Clin Oncol. 2010 Jul 20;28(21):3491-7. doi: 10.1200/JCO.2010.28.4075. Epub 2010 Jun 7. J Clin Oncol. 2010. PMID: 20530271 Free PMC article. Clinical Trial.
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC. Bullock KE, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):465-74. doi: 10.1007/s00280-010-1507-6. Epub 2010 Nov 16. Cancer Chemother Pharmacol. 2011. PMID: 21079958 Free PMC article. Clinical Trial.
118 results